highperformr logo

ChemoCentryx's Overview

Total employees52
HeadquartersSan Carlos
Founded1997

ChemoCentryx, Inc. was a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer. Its research centered on chemokine-based biology, culminating in the development of its flagship product, TAVNEOS® (avacopan), a treatment for ANCA-associated vasculitis. In October 2022, ChemoCentryx was acquired by Amgen for approximately $3.7 billion, integrating its pipeline and TAVNEOS® into Amgen's inflammation portfolio.

Where is ChemoCentryx's Headquarters?

HQ Function

This facility served as the main center for ChemoCentryx's research and development, clinical trial management, and corporate administrative operations before its acquisition.

Notable Features:

The headquarters likely included specialized laboratory facilities for drug discovery and development, alongside modern office spaces designed to foster collaboration and innovation.

Work Culture:

The work culture at ChemoCentryx was reportedly driven by scientific innovation, a commitment to addressing unmet patient needs, and a collaborative environment focused on advancing novel therapies.

HQ Significance:

The San Carlos headquarters was crucial for ChemoCentryx's operations, including the development and initial commercialization efforts for TAVNEOS®, and its location provided access to a rich talent pool and biotech ecosystem.

Values Reflected in HQ: The headquarters reflected ChemoCentryx's dedication to scientific excellence, pioneering research in chemokine biology, and a patient-first approach in tackling complex diseases.

Location:

Before being acquired by Amgen, ChemoCentryx established a global presence primarily through its multi-national clinical trials for its drug candidates. For its lead product, TAVNEOS® (avacopan), it forged strategic commercialization partnerships to reach patients in key international markets, including Europe, Japan, and Canada, while direct US commercialization was handled internally. Its R&D and strategic oversight remained U.S.-based. Post-acquisition, its programs and reach are now part of Amgen's global operational footprint.

Street Address:

835 Industrial Road, Suite 600

City:

San Carlos

State/Province:

CA

Country:

USA

ChemoCentryx's Global Presence

Primarily centralized operations in San Carlos, CA

Address: N/A

International activities, such as clinical trials and commercial partnerships (e.g., with Vifor Pharma for TAVNEOS® in Europe and Japan), were managed from the US headquarters or through its partners, rather than dedicated ChemoCentryx international offices.

Buying Intent Signals for ChemoCentryx

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of ChemoCentryx

As of April 2025, ChemoCentryx' leadership includes:

Thomas J. Schall, Ph.D. - Founder, President, Chief Executive Officer, and Chairman
Susan M. Kanaya - Executive Vice President, Chief Financial and Administrative Officer, and Secretary
Tunde Otulana, M.D. - Chief Medical Officer

Investors of ChemoCentryx

ChemoCentryx has been backed by several prominent investors over the years, including:

Alta Partners
New Enterprise Associates (NEA)
Morgenthaler Ventures
TVM Capital Healthcare (formerly Techno Venture Management)
Vivo Capital
As a publicly traded company (NASDAQ: CCXI), major institutional investors included firms like BlackRock, The Vanguard Group, and State Street Corporation.

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits3

The most significant executive changes for ChemoCentryx as an independent entity in the 12 months prior to its acquisition in October 2022 revolved around the transition of its leadership team following the Amgen takeover. Key executives departed their roles as ChemoCentryx was integrated into Amgen. No major new external executive hires to the independent ChemoCentryx leadership team were publicly announced during this final period.

Departures

Thomas J. Schall, Ph.D., Departed role as ChemoCentryx was acquired by Amgen.
Susan M. Kanaya, Departed role as ChemoCentryx was acquired by Amgen.
Tunde Otulana, M.D., Departed role as ChemoCentryx was acquired by Amgen.

Technology (Tech Stack) used by ChemoCentryx

Discover the tools ChemoCentryx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

ChemoCentryx Email Formats and Examples

Prior to its acquisition by Amgen in October 2022, ChemoCentryx, Inc. utilized corporate email addresses associated with its domain. The formats listed below are based on common patterns and publicly available information for ChemoCentryx as an independent company and are for historical reference, as these email addresses are no longer active for former employees.

Commonly used formats were likely [first_initial][last]@chemocentryx.com (e.g., jdoe@chemocentryx.com) or [first].[last]@chemocentryx.com (e.g., jane.doe@chemocentryx.com). Data suggests flast@chemocentryx.com was a prevalent pattern.

Format

tsmith@chemocentryx.com

Example

70%

Success rate

News and media

Amgen NewsroomOctober 20, 2022

Amgen Completes Acquisition of ChemoCentryx, Inc.

Amgen announced it successfully completed its acquisition of ChemoCentryx for $52 per share in cash, totaling an approximate enterprise value of $3.7 billion. This acquisition brought TAVNEOS® (avacopan), a first-in-class medicine for ANCA-associated vasculitis, into Amgen's portfolio, enhancing its inflammation and nephrology franchises....more

Fierce Pharma (reporting on FDA/ChemoCentryx)October 8, 2021

ChemoCentryx (CCXI) FDA Approval of TAVNEOS™ (avacopan) for ANCA-Associated Vasculitis

The U.S. Food and Drug Administration (FDA) granted approval for ChemoCentryx's TAVNEOS™ (avacopan), an oral selective complement 5a receptor inhibitor, as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. This approval was a major achievement for ChemoCentryx, offering a new therapeutic option for this rare autoimmune disease....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including ChemoCentryx, are just a search away.